Hiring Brief Vetted roles across BioPharma and Biotech commercial, medical affairs, and clinical functions. The recruiter's read on what each one actually signals.
Every week, this Brief puts the recruiter's read on roles that are actually worth your time. Verified companies, current listings, and one line of intelligence on what each role actually signals. Because a job title and a location do not tell you whether this is a company worth your next move.
Most companies post multiple roles. If you see a company that looks right but not the exact title you are looking for, go directly to their careers page.
All links open to company careers pages directly. Roles verified at time of publication against current layoff trackers and M&A activity. If a listing has closed, the company is still building in that function. Go straight to their careers page. Applying does not guarantee an offer.
Week of July 13th, 2026
The companies below caught my attention this week because they're building, launching, or investing in ways that create meaningful career momentum. Every company links directly to its official careers page, so you can spend less time searching and more time focused on the opportunities that align with your next move.
A note on how to use this list: Yaffa Grace & Co. does not represent these companies in their hiring at this time. This is hiring intelligence, curated to help you see who's building. Apply directly on each company's careers page.
New This Week
Mineralys Therapeutics | Hypertension / Cardiometabolic
Lorundrostat is the only aldosterone synthase inhibitor with an FDA-accepted NDA, PDUFA date is December 22, 2026, and Mineralys is already building the commercial launch team with field sales, compliance, and commercial operations roles all posted. Six late-stage clinical trials and two pivotal studies support its candidacy as a best-in-class therapy for uncontrolled and resistant hypertension. The window to be part of this launch is open right now. Careers →
Xenon Pharmaceuticals | Epilepsy / CNS
Positive Phase 3 X-TOLE2 data for azetukalner in focal onset seizures arrived in March 2026, NDA submission is targeted for Q3 2026, and Phase 3 data in major depressive disorder (X-NOVA2) are expected in H1 2027 — giving Xenon a two-indication story building simultaneously. With $1.3 billion in cash and runway into 2029, this is a company building with conviction before it becomes everyone's headline. Careers →
Rhythm Pharmaceuticals | Rare Genetic Obesity / Metabolic Disease
IMCIVREE (setmelanotide) generated $60.1 million in Q1 2026 and just received a third FDA-approved indication — acquired hypothalamic obesity — in March 2026, with more than 150 patient start forms received in the first six weeks after approval. U.S. and international commercial operations are both active, and a Japan NDA is under review, making this one of the more consistently expanding commercial organizations in rare metabolic disease. Careers →
Ascendis Pharma | Rare Endocrine / Oncology
Three approved products — SKYTROFA for pediatric GHD, YORVIPATH for hypoparathyroidism, and YUVIWEL for adult GHD approved February 2026 — give Ascendis one of the most active multi-franchise commercial builds in rare endocrine right now. Field sales, medical affairs, and market access roles are actively posted. Careers →
SpringWorks Therapeutics | Rare Oncology / Desmoid Tumors
OGSIVEO (nirogacestat) delivered $172 million in full-year 2024 U.S. net product revenue as the only approved treatment for desmoid tumors, and the EU Marketing Authorization Application is under review with country-level launches underway. Now operating as a dedicated rare tumor business under Merck KGaA, SpringWorks continues building its commercial and medical affairs team independently. Careers →
Ionis Pharmaceuticals | Cardiometabolic / Rare Neurology
WAINUA (eplontersen) generated $51 million in Q1 2026 with AstraZeneca, and Ionis is simultaneously running two new independent product launches this year while watching the CARDIO-TTRansform Phase 3 readout data expected in H2 2026. Commercial, medical affairs, and market access roles span both cardiometabolic and rare neurology. Careers →
MBX Biosciences | Rare Endocrine / Metabolic Disease
MBX is advancing canvuparatide (MBX 2109), a precision endocrine peptide for chronic hypoparathyroidism, into Phase 3 while building an obesity portfolio with MBX 4291 in Phase 1, giving this company a strategic pipeline across two underserved endocrine conditions. Clinical and early commercial roles are active. Careers →
Liquidia | Pulmonary Arterial Hypertension / PH-ILD
YUTREPIA (treprostinil inhalation powder) is the first and only prostacyclin in dry-powder form, approved for PAH and PH-ILD, and Q1 2026 revenue came in at $132.9 million, up 44% sequentially with a clear line of sight to $1 billion in 2027. The company is actively expanding its sales force and investing in its commercial infrastructure, with three straight profitable quarters. Careers →
your time.
Now know exactly where you stand. 60 minutes with Yaffa. A clear read on your positioning and what needs to change before you send anything.
Still Building and Hiring - Catch Up On Last Week’s List
ACADIA Pharmaceuticals | Rare CNS / Neurology
Two approved rare CNS products, a continuous commercial build across field medical and sales, and advancing neurological programs make ACADIA one of the most reliably active rare disease hiring organizations in biopharma. Careers →
Agios Pharmaceuticals | Rare Hematology
PYRUKYND continues to grow while etavopivat advances toward a pivotal readout in sickle cell disease, making Agios a company worth watching as it continues investing across commercial and medical teams. Careers →
Alnylam Pharmaceuticals | RNAi / ATTR Cardiomyopathy / Rare Disease
AMVUTTRA (vutrisiran) is the only RNAi therapy approved for both ATTR-CM and hereditary ATTR polyneuropathy, targeting an estimated 200,000 Americans most of whom remain undiagnosed. Q1 2026 revenue came in above $1 billion. With 169 open positions including Sr. Director US Commercial and Marketing Technology and Director Commercial Planning, this is one of the most actively hiring organizations in biopharma right now.Careers →
ANI Pharmaceuticals | Rare Disease / Specialty Pharma
ANI continues investing in specialty and rare disease commercialization following strong Cortrophin growth and an expanding field organization. It's a company I expect to keep watching over the coming year. Careers →
Ardelyx | Rare Kidney Disease / GI
Ardelyx holds two approved products: XPHOZAH (tenapanor) for hyperphosphatemia in adults on dialysis and IBSRELA (tenapanor) for IBS-C. Both are fully commercialized, and the company has 87 confirmed open roles across field sales, market access, and operations right now. Zone Director, Field Access Manager, and Field Reimbursement Manager positions are all posted.
Careers →
argenx | Rare Autoimmune — Myasthenia Gravis, CIDP, IgA Nephropathy
argenx has built something rare — three approved indications and a commercial expansion across multiple geographies that shows no signs of slowing. This isn't a single-launch opportunity. It's the kind of sustained organizational growth that creates meaningful careers. Careers →
Arrowhead Pharmaceuticals | Rare Cardiometabolic / RNAi
Arrowhead has an approved product, a competitive landscape that creates commercial urgency, and a program advancing that could expand its opportunity significantly. That combination tends to produce the kind of momentum that makes an organization worth watching closely. Careers →
Bicara Therapeutics | Oncology — Head and Neck Cancer
Bicara is another company quietly building before many people are paying attention. With Breakthrough Therapy Designation and a pivotal trial underway, the company is already investing in the team it will need for the next stage of growth. In my experience, some of the best career opportunities come before a company becomes everyone's headline. Careers →
BridgeBio Pharma | Rare Cardiovascular / Rare Genetic Disease
BridgeBio continues expanding beyond a single-product story, with multiple rare disease programs and ongoing commercial investment making it one of the more interesting companies to watch. Careers →
Celcuity | Oncology — HR+/HER2- Breast Cancer
Celcuity has a significant regulatory decision coming soon for a breast cancer indication where no precision therapy currently exists. When that decision is positive, the commercial build begins immediately. It's one to watch closely right now. Careers →
Cogent Biosciences | Hematology / Oncology
Cogent is preparing for what could be a dual-launch situation with a compressed year-end timeline. Companies that need to build quickly for multiple indications tend to hire decisively, and the window to be inside this one is open now. Careers →
Compass Pathways | Specialty CNS — Treatment-Resistant Depression
Compass continues building toward what could become the first FDA-approved psilocybin therapy for treatment-resistant depression. Companies preparing for first-in-category launches often begin building earlier than people expect. Careers →
Dyne Therapeutics | Rare Neuromuscular Disease
Dyne continues to impress me with the way it's preparing for the future. While clinical development continues, the company is steadily building the commercial foundation needed to support a potential launch. Companies that invest thoughtfully before approval often attract exceptional people who want to help build something meaningful from the ground up. Careers →
Immunic Therapeutics | Immunology - Multiple Sclerosis
Erik Lundgren joined as CEO in May 2026, former Genentech SVP who led the Ocrevus launch. The company raised up to $400M to advance vidofludimus calcium through Phase 3, with top-line data expected by year-end 2026. Medical affairs positions are currently posted as the organization begins building ahead of data.Careers →
Immunocore | Oncology - Uveal Melanoma / TCR-T Bispecific Platform
Immunocore built something genuinely difficult — a commercial organization around a first-in-class therapy in a rare oncology setting. With an advancing pipeline, the hiring is sustained rather than event-driven. That's a distinction worth noting for professionals in specialty oncology. Careers →
Insmed | Rare Pulmonary Disease - Non-CF Bronchiectasis
Insmed created an entirely new treatment category and is now expanding that commercial success internationally, with additional regulatory decisions still ahead. Companies building across three continents in a disease they defined don't come along often. Careers →
Intellia Therapeutics | Gene Therapy / Rare Disease
Intellia is building toward what could be a historic moment in medicine — the first potential in vivo CRISPR therapy advancing toward approval. The commercial infrastructure is already taking shape. If pioneering gene therapy is where you want to build your career, this is one worth watching. Careers →
Krystal Biotech | Rare Dermatology / Gene Therapy
Krystal has moved from pre-commercial ambition to real, growing commercial success, with a product generating meaningful revenue and a platform continuing to advance behind it. This is sustained growth, not a single-launch story. Careers →
Kyowa Kirin | Rare Disease / Oncology
Kyowa Kirin's U.S. portfolio spans rare bone disease (Crysvita) and cutaneous T-cell lymphoma (Poteligeo), and the organization just added a third commercial story: ziftamenib, developed with Kura Oncology, received FDA approval in November 2025 for NPM1-mutated AML. Phase 3 data presented at EHA 2026 showed 90-96% complete remission rates. The oncology commercial build is active.Careers →
Mirum Pharmaceuticals | Rare Pediatric / Rare Liver Disease
Mirum holds two approved products in rare liver disease: LIVMARLI (maralixibat) for Alagille syndrome and PFIC, and volixibat advancing in primary sclerosing cholangitis. Zone Director East, Zone Director West, Regional Account Manager (Metabolics), Senior Product Marketing Manager, and MSL roles are all currently posted. The commercial team is actively building across field and marketing functions.Careers →
Natera | Rare Disease / Genomics Diagnostics
Natera's rare disease division continues to expand alongside broader growth in oncology and prenatal testing. For professionals who work at the intersection of genomics and commercial execution, this is one of the more distinctive opportunities in the space. Careers →
Neurocrine Biosciences | Neurology / Endocrinology
Neurocrine is running two commercial programs simultaneously in different therapeutic areas, which is rarer than it sounds in mid-size specialty pharma. That dual-platform approach creates broad, sustained demand across field, market access, and medical functions. Careers →
Not seeing the opportunity you’re looking for? Tell me what you’re hoping to find. Whether it’s a specific company, therapeutic area, or your next career move, I’d love to hear from you. I read every message.
Tell Me What You’re Looking For →Make sure your career narrative opens the right doors. 60 minutes. $250. Walk away knowing where you stand, how to position yourself, and what to do next. Book a Strategy Session →
Additional Companies
Praxis Precision Medicine | Rare Pediatric Epilepsy / Neurology
Praxis caught my attention because the company isn't waiting for regulatory decisions before investing in its future. Leadership confirmed they're actively building commercial and medical teams while advancing two Breakthrough Therapy-designated programs toward important FDA milestones. When companies begin hiring ahead of potential launches, I pay attention. Those opportunities often become much harder to access once the spotlight arrives. Careers →
Revolution Medicines | Oncology - KRAS-Mutant Tumors
Revolution Medicines has the kind of combination that doesn't come along often - compelling clinical data, leadership in place, and the backing to execute a serious commercial build. The global organization is already taking shape, and that's exactly when the most interesting roles become available. Careers →
Rigel Pharmaceuticals | Oncology / AML / MDS
Rigel acquired Veppanu in May 2026 — the first FDA-approved PROTAC therapy in history — with an August 2026 launch. PROTAC degrades a target previously considered undruggable, and the field team is being assembled this month. For anyone in oncology commercial who wants to be inside a first-in-class mechanism at launch, the window is right now. Careers →
Scholar Rock | Rare Neuromuscular Disease - SM
Scholar Rock has a commercial team already built and staged for an upcoming regulatory decision. In my experience, organizations that prepare this deliberately tend to be thoughtful employers. The best opportunities here are open now — not after the decision arrives. Careers →
Sentynl Therapeutics | Rare Pediatric Disease
Sentynl has built a commercial organization focused entirely on some of the rarest pediatric diseases. Small team, significant impact. If rare pediatric disease is where you want to build your career, this is one of the more meaningful organizations I follow. Careers →
Summit Therapeutics | Oncology - NSCLC
Summit is already behaving like a company that expects to launch. Leadership-level commercial infrastructure and access strategy are being built now, ahead of a near-term regulatory decision. The companies that win launches tend to be the ones that start preparing well before they need to. Careers →
Syndax Pharmaceuticals | Hematology / Oncology
Syndax has two commercial-stage products and a field team that continues to expand. For hematology and oncology professionals who want to build their career within an organization with proven commercial momentum, this one consistently earns its place on my list. Careers →
Tenpoint Therapeutics | Ophthalmology - Presbyopia
Tenpoint launched the first FDA-approved dual-agent eye drop for presbyopia earlier this year and is actively building the U.S. field team now. Early commercial buildouts like this offer something less common: a real opportunity to help shape how an organization grows. Careers →
Travere Therapeutics | Rare Kidney Disease - IgA Nephropathy
Travere has a commercial model that's already working - strong product growth and continued investment in senior leadership. This isn't a company still figuring out its strategy. It's one executing it, and continuing to build the team that does. Careers →
UCB | Immunology / Neurology
UCB has three approved specialty products running simultaneously through overlapping specialist accounts, which creates continuous and sustained demand across field, access, and medical functions. It's one of the most consistently active specialty commercial organizations I follow. Careers →
Ultragenyx Pharmaceutical | Rare Metabolic Disease / Gene Therapy
Ultragenyx is approaching what could be a defining window - two potential regulatory decisions for pediatric diseases with no approved treatment. In my experience, the professionals who position themselves early in moments like this are the ones who end up in the most meaningful roles. Careers →
Viridian Therapeutics | Ophthalmology / Thyroid Eye Disease
Lumvoa (veligrotug) received FDA approval on June 26, 2026 — the first thyroid eye disease therapy labeled for both active and chronic disease. That label distinction changes the entire commercial conversation for this patient population. The organization is ten days into launch and building the field and commercial infrastructure. Careers →
Zenas BioPharma | Immunology / IgG4-Related Disease
Obexelimab's Phase 3 INDIGO trial showed a 56% reduction in flare rate — data published in the New England Journal of Medicine. Zenas submitted the BLA on May 28, 2026. IgG4-related disease has no FDA-approved treatment, which means this is a first-mover commercial build into a completely open market. Careers →